Introduction {#sec0005}
============

In December 2019, the coronavirus disease (COVID-19) occurred in Wuhan, China, and spread rapidly to become public health emergency of international concern, which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection ([@bib0010], [@bib0015]). Up to March 2, 2020, a total of 80,174 confirmed cases including 49,315 in Wuhan have been reported in China. The typical symptoms of COVID-19 include: fever, dry cough, fatigue, sputum production, and shortness of breath. All people are susceptible to COVID-19, including infants and children ([@bib0075], [@bib0045], [@bib0055]), and human to human transmission has been confirmed ([@bib0080]).

No specific drugs have been identified for COVID. The currently widely used treatments include, antiviral treatment such as Arbidol and Ribavirin, antibiotics, corticosteroid, noninvasive or invasive ventilation, and extracorporeal membrane for critically ill patients ([@bib0030], [@bib0085], [@bib0025]). Multiple platforms are under development for COVID-19 vaccines at pandemic speed ([@bib0040]).

The diagnosis of COVID-19 is mainly based on typical symptoms, bilateral involvement on chest radiographs, and exposure to infected patients, and confirmed by positive nucleic acid test of SARS-CoV-2 from numerous types of specimens. Reverse-transcriptase-polymerase-chain-reaction (RT-PCR) is the most common method for SARS-CoV-2 detection by targeting the ORF1ab, N, or E genes. Oropharyngeal and nasopharyngeal swabs were most frequently used samples ([@bib0050]). However, negative oropharyngeal and nasopharyngeal swabs could not rule out COVID-19, as some patients got positive SARS-CoV-2 from other types of specimen, including bronchoalveolar lavage fluid (BALF), anal swab, stool, and urine ([@bib0065], [@bib0070]). False negative SARS-CoV-2 occurred, and positive RT-PCR test results of SARS-CoV-2 were observed in patients recovered from COVID-19 ([@bib0035]). Evaluation of different types of specimen may promote the positive rate (positive tests/total tests), and be helpful for the decision of discharge from hospital.

Since February 16 2020, SARS-CoV-2 nucleic acid detections using both nasopharyngeal and oropharyngeal swabs have been performed simultaneously for some patients in our Hospital. We reviewed the medical record from February 16, 2020 to March 2, 2020, and compared the performance between nasopharyngeal and oropharyngeal swabs in SARS-CoV-2 detection from 353 patients who received tests with both specimens simultaneously.

Method {#sec0010}
======

Patient selection {#sec0015}
-----------------

COVID-19 was diagnosed based on the WHO interim guidance ([@bib0065]). Patients who showed COVID-19 like symptoms, such as fever, cough, and fatigue, were initially screened in community hospitals for fever and chest X-ray. If patients had fever or chest X-ray abnormality, they would be further admitted to the fever clinic as outpatient in designated hospitals for COVID-19 to get SARS-CoV-2 RT-PCR test and chest Computed Tomography (CT) scanning. Our hospital was one of the designated hospitals for COVID-19. All inpatients had positive result in SARS-CoV-2 RT-PCR test before hospitalization. Some of the inpatients in our hospital were transferred from other hospital, as our hospital was one of the designated hospitals for severe and very severe COVID-19 patients. A total of 353 patients were collected in this study, including 192 outpatients and 161 inpatients. This study was approved by Tongji Hospital Ethics Committee.

Nasopharyngeal and oropharyngeal swabs collection {#sec0020}
-------------------------------------------------

A nasopharyngeal swab was collected from single nostril according to a detailed video in a previously published study ([@bib0005]). A oropharyngeal swab was collected from both sides of throat according to a published video by Chinese Society of Laboratory Medicine (<http://www.cslm.org.cn/cn/news.asp?id=74.html>). A nasopharyngeal swab and an oropharyngeal swab for each patient were taken at the same time as each other, and sent to SARS-CoV-2 RT-PCR test simultaneously.

Data collection {#sec0025}
---------------

Data including age, sex, and SARS-CoV-2 RT-PCR results were extracted from electronic medical records up to March 2, 2020. Only the cases who received tests with both nasopharyngeal and oropharyngeal swabs simultaneously were included in our study.

Laboratory confirmation {#sec0030}
-----------------------

Laboratory confirmation of SARS-CoV-2 was performed in the department of laboratory medicine using RT-PCR. Respiratory tract specimen was suggested for SARS-CoV-2 RT-PCR test, including nasopharyngeal and oropharyngeal swab, sputum and bronchoalveolar lavage fluid (BALF). Oropharyngeal swab was widely used in the beginning of COVID-19 outbreak. Specimens were collected and stored in a collection tube with 5 mL virus preservation solution. RNA was isolated with Tianlong PANA9600 automatic nucleic acid extraction system (Tianlong, Xi'an, China). The RT-PCR assay detecting both nucleocapsid protein (N) and open reading frame 1ab (ORF1ab) genes simultaneously gifted by DAAN GENE (Guangzhou, China). RT-PCR assay was performed with Tianlong Gentier 96E real-time PCR system in a volume of 25 μL using the following conditions: 50 °C for 15 min, 95 °C for 15 min, 45 cycles of 94 °C for 15 s, 55 °C for 45 s for fluorescence collection. The cutoff cycle threshold (Ct) value was 40 for both genes, and the Ct values of both genes were less than 40 was defined as positive.

Statistical analysis {#sec0035}
--------------------

Data were presented as medians with interquartile (IQR) ranges and range. Categorical variables were analyzed using the *χ* ^2^ or Fisher\'s exact test. Correlation and consistency were analyzed using McNemar test and Kappa Coefficient. All analyses were done with SPSS 16. *P* value \<0.05 was considered statistically significant.

Result {#sec0040}
======

Of the 353 patients (outpatients, 192; inpatients, 161) studied, the median age was 54 years (range, 20 to 88 years), and 177 (50.1%) were women. The positive rates from total, outpatient, and inpatient, were 19.0% *vs.* 7.6%, 7.3% *vs.* 6.3%, and 32.9% *vs.* 9.3% in nasopharyngeal and oropharyngeal swabs, respectively ([Table 1](#tbl0005){ref-type="table"} ). The positive rates from both nasopharyngeal and oropharyngeal swabs in outpatient decreased sharply to less than 10%, much lower than early stage of COVID-19 outbreak ([@bib0050]). The combined positive rate was calculated if either result from nasopharyngeal and oropharyngeal swabs was positive, and it increased to 21.5%, 9.9%, and 35.4% in total, outpatient, and inpatient respectively, slightly higher those from nasopharyngeal swabs, which was 19.0%, 7.3%, and 32.9%, respectively.Table 1Comparison of positive ratio between nasopharyngeal and oropharyngeal swabs.Table 1GroupNumberAge (IQR, range), yearCombined positiveNasopharyngeal swab positiveOropharyngeal swab positive*P* value**Total**35354 (39 to 65, 20 to 88)76/353 (21.5%)67/353 (19.0%)27/353 (7.6%)**0.000**Outpatient192 (54.4%)49 (36 to 61, 20 to 88)19/192 (9.9%)14/192 (7.3%)12/192 (6.3%)0.685Inpatient161 (45.6%)61 (49 to 69, 26 to 87)57/161 (35.4%)53/161 (32.9%)15/161 (9.3%)**0.000Male**176 (49.9%)54 (39 to 65, 20 to 87)45/176 (25.6%)42/176 (23.9%)16/176 (9.1%)**0.000**Male outpatient93 (52.8%)49 (38 to 62, 20 to 87)13/93 (14.0%)12/93 (12.9%)7/93 (7.5%)0.226Male inpatient83 (47.2%)59 (44 to 67.5, 27 to 87)32/83 (38.6%)30/83 (36.1%)9/83 (10.8%)**0.000Female**177 (50.1%)54 (39 to 65, 23 to 88)31/177 (17.5%)25/177 (14.1%)11/177 (6.2%)**0.014**Female outpatient99 (55.9%)47 (35 to 59, 23 to 88)6/99 (6.1%)2/99 (2.0%)5/99 (5.1%)0.248Female inpatient78 (44.1%)62 (52.3 to 69, 26 to 84)25/78 (32.1%)23/78 (29.5%)6/78 (7.7%)**0.000**[^2]

Moreover, among the inpatient group, the positive rate was quite different between nasopharyngeal and oropharyngeal swabs, 32.9% *vs.* 9.3%. As all the 49,315 infected patients must be hospitalized and evaluated for discharge from hospital based on the result of SARS-CoV-2 nucleic acid detection, oropharyngeal swab may cause remarkable false negative results and lead to the discharge of infected patients from hospital.

Male patients showed significantly higher positive rate in total male population than total female population, and in male outpatients than female outpatients from nasopharyngeal but not oropharyngeal swabs ([Table 2](#tbl0010){ref-type="table"} ).Table 2Comparison of positive ratio between male and female patientsTable 2GroupTotalOutpatientInpatientMaleFemale*P* valueMaleFemale*P* valueMaleFemale*P* valueNasopharyngeal swab positive42/17625/177**0.020**12/932/99**0.004**30/8323/780.369Oropharyngeal swab positive16/17611/1770.3097/935/990.4799/836/780.492[^3]

Among the 27 positive results in oropharyngeal swabs, 18 cases were also positive in nasopharyngeal swabs, accounting for 66.7%, and the remaining 9 patients included 5 outpatients and 4 inpatients. Among the 67 positive results in nasopharyngeal swabs, 49 cases were negative in oropharyngeal swabs, accounting for 73.1%. The consistency between from nasopharyngeal and oropharyngeal swabs were poor ([Table 3](#tbl0015){ref-type="table"} ).Table 3Correlation of results from nasopharyngeal and oropharyngeal swabsTable 3Oropharyngeal swabNasopharyngeal swabPositiveNegativePositive189Negative49277[^4]

Discussion {#sec0045}
==========

Two consecutively negative RT-PCR test results in specimens from respiratory tract separated by at least 1 day is required for the evaluation of discharge from hospital, and oropharyngeal swab samples were still the most common sample ([@bib0075]). However, false negative result may occur in the late stage of hospitalization. Positive RT-PCR test results were found in recovered patients two weeks after discharge ([@bib0035]). Live SARS-CoV-2 has been found from stool in some patients ([@bib0065]). In our study, positive RT-PCR test results showed quite difference between nasopharyngeal and oropharyngeal swabs. 73.1% of nasopharyngeal positive cases were negative in oropharyngeal swab, indicating false negative results may occur using oropharyngeal swab only. These results suggest that nasopharyngeal swabs showed higher positive rate than oropharyngeal swabs for SARS-CoV-2 detection, and oropharyngeal swabs may result in a worryingly high false negative rate.

The reduced susceptibility of females to COVID-19 had been observed in our study, consistent with previous studies ([@bib0020]). Moreover, a recent meta-analysis found that among the included 50,488 Chinese patients, male accounted more than female with an Odds of 1.13 ([@bib0060]).

In conclusion, nasopharyngeal swabs showed higher positive rate than oropharyngeal swabs. Our study suggests that nasopharyngeal swabs may be more suitable than oropharyngeal swab at this late stage of COVID-19 outbreak.
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